Blood-brain barrier permeable β-blockers association with Alzheimer's disease cerebrospinal fluid biomarkers levels in non-demented individuals
Journal of Alzheimer’s Disease · 2024
DOI: 10.1177/13872877241293812 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Mariateresa Buongiorno und 11 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain. Hauptthemen laut MEDLINE: Alzheimer Disease, Blood-Brain Barrier, Biomarkers, Amyloid beta-Peptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: Innovative Medicines Initiative, Alzheimer's Association, Instituto de Salud Carlos III.
Themen: Demenz
Abstract (Originalsprache)
β-blockers that easily cross the blood-brain barrier (BBB) seem to diminish the risk of Alzheimer's disease (AD), hypothetically facilitating waste clearance. However, their effect on AD pathophysiological markers is unknown. We compared cerebrospinal fluid (CSF) AD biomarker levels among non-demented individuals taking low, intermediate, or high BBB permeable β-blockers in two samples (ADNI: n = 216; EPAD: n = 79). We found that CSF amyloid-β levels were higher in individuals taking highly permeable β-blockers in the ADNI sample. This result was not replicated in EPAD, in which diminished levels of pTau181 and tTau were observed. These data suggest that β-blockers may impact AD pathophysiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
- Neurovascular Diseases Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
- Hospital del Mar Research Institute, Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.
- Department of Neurology, Fundació Assistencial Mútua Terrassa, Terrassa, Spain.
ORCID-Profile: Mariateresa Buongiorno
Förderung
- Innovative Medicines Initiative
- Alzheimer's Association
- Instituto de Salud Carlos III
- National Institute on Aging
Zitieren
APA
Buongiorno, M., Sánchez-Benavides, G., Marzal-Espí, C., Giraldo, D. M., Krupinski, J., Cullell, N., Grau-Rivera, O., Suárez-Calvet, M., Gispert, J. D., de la Sierra, A., Alzheimer's Disease Neuroimaging Initiative **, & and the European Prevention of Alzheimer's Disease (EPAD) Consortium (2024). Blood-brain barrier permeable β-blockers association with Alzheimer's disease cerebrospinal fluid biomarkers levels in non-demented individuals. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877241293812
Vancouver
Buongiorno M, Sánchez-Benavides G, Marzal-Espí C, Giraldo DM, Krupinski J, Cullell N, et al. Blood-brain barrier permeable β-blockers association with Alzheimer's disease cerebrospinal fluid biomarkers levels in non-demented individuals. Journal of Alzheimer’s Disease. 2024. doi:10.1177/13872877241293812
BibTeX
@article{Buongiorno2024,
author = {Buongiorno, Mariateresa and Sánchez-Benavides, Gonzalo and Marzal-Espí, Clara and Giraldo, Darly Milena and Krupinski, Jerzy and Cullell, Natalia and Grau-Rivera, Oriol and Suárez-Calvet, Marc and Gispert, Juan Domingo and de la Sierra, Alex and Alzheimer's Disease Neuroimaging Initiative **, Alzheimer's Disease Neuroimaging Initiative ** and and the European Prevention of Alzheimer's Disease (EPAD) Consortium, and the European Prevention of Alzheimer's Disease (EPAD) Consortium},
title = {Blood-brain barrier permeable β-blockers association with Alzheimer's disease cerebrospinal fluid biomarkers levels in non-demented individuals},
journal = {Journal of Alzheimer’s Disease},
year = {2024},
doi = {10.1177/13872877241293812}
}
EUVIMED